共查询到20条相似文献,搜索用时 453 毫秒
1.
目的观察不同来源的异基因造血干细胞移植治疗白血病的疗效并探讨主要并发症的处理方案。方法对2001年9月至2007年3月第四军医大学西京医院血液科76例白血病患者行异基因造血干细胞移植治疗,其中慢性粒细胞白血病34例,急性髓性白血病24例,急性淋巴细胞白血病15例,T细胞淋巴瘤/白血病3例。人类白细胞抗原(HLA)全相合的同胞供者57例,1个HLA位点不合同胞供者3例,HLA单倍型半相合同胞供者7例,非血缘供者9例。预处理方案采用改良的马利兰联合环磷酰胺(BUCY)或改良的环磷酰胺联合全身放疗及阿糖胞苷或鬼臼乙叉甙(CyTBI Ara-c/VP-16)方案。采用标准的环孢素A(CsA)联合短期甲氨蝶呤(MTX)方案预防移植物抗宿主病(GVHD);无关供者移植加用抗人胸腺细胞球蛋白,单倍型半相合移植同时加用CD25单克隆抗体。结果96.1%(73/76)获得植入。24.7%(18/73)出现急性GVHD,32.9%(24/73)出现慢性GVHD;合并重症肝静脉闭塞病2例;并发纯红细胞性再生障碍性贫血5例。随访3~72个月,现存活56.6%(43/76),43.4%(33/76)在移植后1~36个月时死亡,19例死于白血病复发,14例死于移植相关并发症。结论多种来源的异基因造血干细胞移植是治疗白血病的有效方法,于慢性粒细胞白血病慢性期、急性白血病缓解期移植效果较好,移植前处于高危难治状态的病例复发率仍较高。 相似文献
2.
异基因造血干细胞移植治疗白血病20例临床观察 总被引:1,自引:0,他引:1
目的探讨不同类型异基因造血干细胞移植(allo-HSCT)治疗白血病的疗效、造血重建及存活情况。方法哈尔滨血液病肿瘤研究所2003年3月至2006年7月进行异基因造血干细胞移植的白血病患者20例,其中同胞间人类白细胞抗原(HLA)相合的异基因外周血造血干细胞移植(allo-PBSCT)12例,无亲缘关系HLA不全相合脐血移植(UCBT)4例,无关供者的异基因外周血干细胞移植(其中1例HLA-CW位点亚型不合)3例,无关供者骨髓移植1例(经过去除红细胞处理)。结果19/20受者获造血重建,UCBT患者造血重建速度较HLA相合的同胞allo-PBSCT慢,异基因造血干细胞移植后20例患者中发生急性移植物抗宿主病(aGVHD)7例,其中4例Ⅰ~Ⅱ度,3例Ⅲ~Ⅳ度。3例患者死于复发,3例死于移植物抗宿主病(GVHD),另15例至今仍无病存活,中位存活时间30(1~41)个月。结论allo-HSCT是目前治愈白血病的有效方法,对于无同胞HLA相合的供者,选择较高细胞数量,HLA1~2个位点不合的UCBT仍然有效、可行。 相似文献
3.
单倍型相合骨髓移植治疗难治复发恶性淋巴瘤初步观察 总被引:2,自引:0,他引:2
目的:探讨应用单倍型未去T细胞的异基因骨髓移植(allo-BMT)治疗难治复发恶性淋巴瘤的疗效、造血重建、并发症及生存情况。方法:采用清髓性未去T细胞亲缘单倍型相合allo-BMT治疗11例难治性晚期淋巴瘤患者。供者用粒细胞刺激集落因子(G-CSF)皮下注射,连续7d后采髓,预处理方案采用环磷酰胺、全身照射及阿糖胞苷(CyTBI加Ara-C)。移植物抗宿主病(GVHD)预防采用联合免疫抑制剂包括环孢素A、短程氨甲碟呤、抗胸腺细胞球蛋白、CD25单克隆抗体及霉酚酸酯。结果:患者移植后均获造血重建,中性粒细胞>0.5×109/L及PLT>20×109/L的平均时间分别为17.2及21.3d,植入证据检测证实为完全供者造血。4例发生急性GVHD(aGVHD),3例发生慢性GVHD(cGVHD),中位随访1136(31~2521)d,2例死于感染,1例死于aGVHD,1例死于复发,无病生存7例。结论:清髓性未去T细胞亲缘单倍型相合allo-HSCT是治疗伴骨髓侵犯以及自体造血干细胞移植后复发难治性晚期恶性淋巴瘤有效方法,如有合适供者,可考虑作为年轻晚期患者的挽救治疗。 相似文献
4.
《临床血液学杂志》2015,(4)
目的:探讨父母HLA 10/10相合不去除T细胞的外周血造血干细胞移植治疗恶性血液病的植入情况、疗效和相关并发症。方法:预处理采用改良的Bu/Cy方案,用低剂量的兔抗人T淋巴细胞球蛋白、环孢素A、吗替麦考酚酯和短程甲氨蝶呤预防移植物抗宿主病(GVHD)。回输G-CSF动员的外周血干细胞,输注单个核细胞中位数为7.830(7.320~10.004)×108/kg,CD34+细胞中位数为4.59(3.68~5.32)×106/kg。结果:4例患者均达完全供者植入,粒系植入时间为16(11~16)d,血小板植入时间为22(11~29)d。发生Ⅱ度急性GVHD1例,发生率25%。发生慢性GVHD 3例,广泛型1例。中位随访267(178~1903)d,死亡1例(非复发死亡),复发1例(为高危患者),无复发存活2例。结论:低剂量ATG用于父母HLA 10/10相合供者异基因造血干细胞移植治疗高危恶性血液病是比较安全、有效的方案。 相似文献
5.
《临床血液学杂志》2017,(2)
目的:评估异基因造血干细胞移植(allo-HSCT)治疗重型再生障碍性贫血(SAA)Ⅱ型的疗效和安全性。方法:回顾性分析接受allo-HSCT治疗的22例SAAⅡ患者的临床资料,其中同胞相合供者移植10例,无关供者移植12例;18例行外周血造血干细胞移植,4例行骨髓联合外周血造血干细胞移植。预处理方案为环磷酰胺+抗人胸腺细胞球蛋白±氟达拉滨±白消安±低剂量TBI;采用环孢霉素A或他克莫司、短疗程甲氨蝶呤±霉酚酸酯预防移植物抗宿主病(GVHD)。回输单个核细胞中位数13.55(5.12~25.90)×10~8/kg,CD34~+细胞中位数7.30(2.19~40.32)×10~6/kg。结果:20例(90.91%)患者获得造血重建,可评估患者的中性粒细胞和血小板的中位植入时间分别为12(9~22)d和13(9~28)d。移植后2年急性GVHD、慢性GVHD和移植排斥、移植相关死亡累积发生率分别为40.00%、30.00%、9.09%和22.73%。细菌血流感染率22.73%,肺部侵袭性真菌病发生率40.91%,巨细胞病毒和EBV感染率分别为75.00%和50.00%;心、肝、肾功能不全发生率分别为45.45%、13.64%和36.36%。中位随访23(10~68)个月,17例患者生存,预期2年总生存率77.27%,预期2年无病生存率72.73%。单因素分析结果显示,移植后发生严重(Ⅱ~Ⅳ度)急性GVHD和重要脏器功能不全可显著降低allo-HSCT治疗SAAⅡ的疗效(P=0.018、0.009)。结论:同胞相合供者和无关HLA匹配供者alloHSCT是治疗SAAⅡ的有效手段。 相似文献
6.
对 1例难治性急性粒 -单细胞白血病 (AML - M4 b)患者施行异基因外周血造血干细胞移植 (allo-PBSCT ) ,以 Cy/ TBI方案预处理后 ,输注 HL A完全相合的同胞供者经 G- CSF动员的外周血单个核细胞(PBMNCs) 9.0× 10 8/ kg,其中 CD34 细胞 6 .2 5× 10 6 / kg;移植物抗宿主病 (GVHD)的预防用 Cs A MTX方案。结果 : 15天时 ,外周血中性粒细胞 >0 .5× 10 9/ L,血小板 >5 0× 10 9/ L; 30天时 ,外周血三系均完全恢复正常。仅有 度皮肤 GVHD发生。认为对于难治性白血病 ,如有 HL A相合供者 ,应及早行异基因造血干细胞移植 (allo-HSCT)特别是 allo- PBSCT,具有受者造血与免疫功能重建快等优点 相似文献
7.
《临床血液学杂志》2017,(3)
目的:评估异基因造血干细胞移植(allo-HSCT)治疗重型再生障碍性贫血(SAA)Ⅱ型的疗效和安全性。方法:回顾性分析接受allo-HSCT治疗的22例SAAⅡ患者的临床资料,其中同胞相合供者移植10例,无关供者移植12例;18例行外周血造血干细胞移植,4例行骨髓联合外周血造血干细胞移植。预处理方案为环磷酰胺+抗人胸腺细胞球蛋白±氟达拉滨±白消安±低剂量TBI;采用环孢霉素A或他克莫司、短疗程甲氨蝶呤±霉酚酸酯预防移植物抗宿主病(GVHD)。回输单个核细胞中位数13.55(5.12~25.90)×10~8/kg,CD34~+细胞中位数7.30(2.19~40.32)×10~6/kg。结果:20例(90.91%)患者获得造血重建,可评估患者的中性粒细胞和血小板的中位植入时间分别为12(9~22)d和13(9~28)d。移植后2年急性GVHD、慢性GVHD和移植排斥、移植相关死亡累积发生率分别为40.00%、30.00%、9.09%和22.73%。细菌血流感染率22.73%,肺部侵袭性真菌病发生率40.91%,巨细胞病毒和EBV感染率分别为75.00%和50.00%;心、肝、肾功能不全发生率分别为45.45%、13.64%和36.36%。中位随访23(10~68)个月,17例患者生存,预期2年总生存率77.27%,预期2年无病生存率72.73%。单因素分析结果显示,移植后发生严重(Ⅱ~Ⅳ度)急性GVHD和重要脏器功能不全可显著降低allo-HSCT治疗SAAⅡ的疗效(P=0.018、0.009)。结论:同胞相合供者和无关HLA匹配供者alloHSCT是治疗SAAⅡ的有效手段。 相似文献
8.
HLA半相合非清髓异基因造血干细胞移植治疗难治性急性白血病1例 总被引:1,自引:0,他引:1
目的探讨HLA半相合非清髓异基因造血干细胞移植(NAST)在治疗难治性急性白血病中的作用。方法2002-06采用非清髓预处理的NAST治疗军事医学科学院附属307医院难治性急性髓性白血病患者1例。预处理方案主要由抗淋巴细胞球蛋白(ATG)、阿糖胞苷(Ara-C)、氟达拉滨(Flu)和环磷酰胺(CTX)等组成。移植物抗宿主病(GVHD)的预防采用环孢素A(CSA)、霉酚双酯(MMF)、甲氨蝶呤(MTX)和CD25单抗。结果患者移植过程顺利,于移植后第100d转为完全供者型植入。患者于移植后出现皮肤Ⅰ度GVHD,经治疗后好转。结论应用HLA半相合NAST治疗难治性急性白血病患者,简便安全,疗效好,为无HLA相合供者的白血病患者治疗开辟了新的治疗手段。 相似文献
9.
目的 探讨人类白细胞抗原(HLA)单倍相合造血干细胞移植(HSCT)治疗恶性血液病的疗效和主要并发症.方法 对2004年7月至2006年12月第三军医大学附属新桥医院收治的35例恶性血液病患者进行HLA单倍相合亲缘供者HSCT.采用延长、强化联合免疫抑制促进植入、抗胸腺细胞球蛋白(ATG)加强预防移植物抗宿主病(GVHD)、粒细胞集落刺激因子(G-CSF)动员的骨髓(BM)加外周血干细胞(PBSC)混合移植方案.结果 所有患者均重建供者造血.18例(51.4%)发生急性GVHD(aGVHD),其中Ⅰ度8例,Ⅱ度5例,Ⅲ度3例,Ⅳ度2例,Ⅱ~Ⅳ度aGVHD累积发生率为28.6%.12例(34.3%)发生慢性CVHD(cGVHD),均为局限性.23例患者存活,总存活率为65.7%,2年无病存活率(DFS)为62.9%.12例患者死亡,7例死于复发,5例死于移植相关合并症,其中肺部感染2例,Ⅳ度GVHD 2例,巨细胞病毒(CMV)感染1例.结论 随着预处理方案、GVHD预防方案及移植物成分的优化,HLA单倍相合造血干细胞移植的疗效明显改善,已成为治疗恶性血液病的重要方法. 相似文献
10.
异基因造血干细胞移植治疗黏多糖病Ⅰ型1例 总被引:1,自引:0,他引:1
目的:MPS-1H是一种进展型黏多糖代谢性遗传病,常导致早期死亡.我们进行了异基因造血干细胞移植(allo-HSCT)治疗该病的初步尝试.方法:1例2岁MPS-1H幼儿接受了其HLA不全相合姐姐allo-HSCT.预处理方案为马利兰、环磷酰胺和抗胸腺细胞球蛋白;移植物抗宿主病(GVHD)预防包括环孢素、短程甲氨喋呤、赛尼哌和骁悉.移植后评价植入、不良反应和疗效.结果:完全供者嵌合14 d,中性粒细胞>0.5×109/L,11 d,血小板>50×109/L,28 d.未发生严重的GVHD和移植物衰竭.植入后MPS-1H的临床症状明显改善,认知能力持续增加.结论:早期allo-HSCT可减轻疾病的症状,改善生活质量和存活. 相似文献
11.
目的胰岛素瘤是最常见的胰腺神经内分泌肿瘤,因其临床表现多样,导致诊断困难。影像学诊断尤其是超声内镜(EUS)在胰岛素瘤的诊断中起着重要作用,拥有较高的敏感性和特异性。本研究拟通过明确胰岛素瘤的解剖分布特点,以期有助于提高影像学的诊断准确率和降低漏诊率,尤其是在教育和培训实践中对于EUS的学习者更具有指导价值。
方法回顾性分析解放军总医院第一医学中心病案资料数据库1993年1月至2019年11月经外科手术、病理确诊为胰岛素瘤的患者的临床资料,检索方法采取搜索术后病理诊断为"胰岛素瘤"的病例,通过查阅病例的方法,提取出胰岛素瘤的大小和解剖分布等数据,进一步分析其特点。
结果共检索到确诊为胰岛素瘤的患者116例,其中,男45例、女71例,年龄13~76岁,平均年龄(44.4±14.85)岁。胰岛素瘤单发110例(94.8%)、多发6例(5.2%)。位置分布:头颈部46例(39.7%),单发45例、多发1例;体尾部68例(58.6%),单发65例、多发3例;全胰腺多发2例(1.7%)。病变大小特点:最大径0.4~3.4 cm,平均大小(1.53±0.58)cm。≤1 cm 29例、>1 cm而≤1.5 cm41例、>1.5 cm而≤2.0 cm28例,≤3 cm 15例,>3 cm 3例。年龄与肿瘤的大小相关,≤44岁患者肿瘤平均大小为(1.36±0.51)cm、>44岁患者肿瘤平均大小为(1.70±0.60)cm,P<0.05。头颈部的肿瘤大于体尾部的肿瘤,头颈部肿瘤平均大小(1.66±0.63)cm,体尾部(1.42±0.52)cm,P<0.05。
结论胰岛素瘤在胰腺体尾部较头颈部更好发;绝大多数单发,但可以全胰腺多发;多数小于1.5 cm,肿瘤的大小与患者年龄和肿瘤的解剖分布相关。 相似文献
12.
Most adenomas and carcinomas of the small intestine and extrahepatic bile ducts arise in the region of the papilla of Vater. In familial adenomatous polyposis (FAP) it is the main location for carcinomas after proctocolectomy. In many cases symptoms due to stenosis lead to diagnosis at an early tumor stage. In about 80%, curative intended resection is possible. Operability is the most relevant prognostic factor. Most ampullary carcinomas resp. carcinomas of the papilla of Vater develop from adenomatous or flat dysplastic precursor lesions. They can be sited in the ampulloduodenal part of the papilla of Vater, which is lined by intestinal mucosa. They also can develop in deeper parts of the ampulla, which are lined by pancreaticobiliary duct mucosa. Intestinal-type adenocarcinoma and pancreaticobiliary-type adenocarcinoma represent the main histological types of ampullary carcinoma. Furthermore, there exist unusual types and undifferentiated carcinomas. Many carcinomas of intestinal type express the immunohistochemical marker profile of intestinal mucosa (keratin 7?, keratin 20+, MUC2+). Carcinomas of pancreaticobiliary type usually show the immunohistochemical profile of pancreaticobiliary duct mucosa (keratin 7+, keratin 20?, MUC2?). Even poorly differentiated carcinomas, as well as unusual histological types, may conserve the marker profile of the mucosa they developed from. These findings underline the concept of histogenetically different carcinomas of the papilla of Vater which develop either from intestinal- or from pancreaticobiliary-type mucosa of the papilla of Vater. Molecular alterations in ampullary carcinomas are similar to those of colorectal as well as pancreatic carcinomas, although they appear at different frequencies. In future studies, molecular alterations in ampullary carcinomas should be correlated closely with the different histologic tumor types. Consequently, the histologic classification should reflect the histogenesis of ampullary tumors from the two different types of papillary mucosa. 相似文献
13.
Sergio Muntoni Paola Tagliamonte Federico Sirigu Giovanni Umberto Corsini 《Acta diabetologica》1973,10(6):1300-1307
Summary Palmitic acid oxidation in rat diaphragm homogenate is depressed by biguanide concentrations that are still incapable of inhibiting
oxidative phosphorylation. Glucose oxidation is not directly effected by the same biguanide concentrations: however, the inhibitory
effect of palmitic acid on glucose oxidation is partly removed by biguanides. Inhibition of fatty acid oxidation, which accounts
for most of the metabolic effects caused by these drugs, can be regarded as the fundamental mechanism of action of biguanides.
There is some evidence suggesting that these drugs might interact with carnitine, thus preventing long-chain fatty acids from
being transported across the mitochondrial membrane to the site of oxidation.
Traduzione a cura degli AA. 相似文献
14.
P. Brar G.Y. Kwon I.I. Egbuna S. Holleran R. Ramakrishnan G. Bhagat P.H.R. Green 《Digestive and liver disease》2007,39(1):26-29
BACKGROUND AND AIM: Both the clinical presentation and the degree of mucosal damage in coeliac disease vary greatly. In view of conflicting information as to whether the mode of presentation correlates with the degree of villous atrophy, we reviewed a large cohort of patients with coeliac disease. PATIENTS AND METHODS: We correlated mode of presentation (classical, diarrhoea predominant or atypical/silent) with histology of duodenal biopsies and examined their trends over time. RESULTS: The cohort consisted of 499 adults, mean age 44.1 years, 68% females. The majority had silent coeliac disease (56%) and total villous atrophy (65%). There was no correlation of mode of presentation with the degree of villous atrophy (p=0.25). Sixty-eight percent of females and 58% of males had a severe villous atrophy (p=0.052). There was a significant trend over time for a greater proportion of patients presenting as atypical/silent coeliac disease and having partial villous atrophy, though the majority still had total villous atrophy. CONCLUSIONS: Among our patients the degree of villous atrophy in duodenal biopsies did not correlate with the mode of presentation, indicating that factors other than the degree of villous atrophy must account for diarrhoea in coeliac disease. 相似文献
15.
血吸虫童虫是宿主免疫系统攻击的重要靶标,包括皮肤型、肺型和肝门型童虫。宿主分子对童虫生长发育具有重要作用。童虫生长发育机制包括免疫调节、信号转导、性别发育及凋亡等。肌动蛋白、组织蛋白酶、烯醇化酶和葡萄糖基转移酶等分子为血吸虫童虫生长发育的重要分子。本文对血吸虫童虫生长发育及其机制的研究进展做一综述。 相似文献
16.
目的对临床分离的耐多药结核分枝杆菌相关基因的突变特征进行分析。方法对124例耐多药结核分枝杆菌以及50株敏感株的耐药相关基因(包括异烟肼inh A、kat G、oxyR-ahp C间隔区以及利福平rpo B)进行序列测定,分析其基因突变情况。结果异烟肼耐药inh A基因突变率为14.5%;kat G基因突变率为70.2%(87/124),主要位于315位;oxyR-ahp C间隔区突变率为15.3%;inh A、kat G两种基因同时突变率75.0%,三种基因同时突变率为89.5%。利福平rpo B基因突变的检出率高达95.2%,突变主要发生在531、526、516位点。结论我省耐多药菌异烟肼耐药相关基因最常见突变为kat G 315、inh A C-T(-15)、axyR-ahp C间隔区(-10)C-T,利福平为rpo B531、526、516。结合MDR-TB耐药相关基因的特征分析,可以建立一种快速、准确、特异的适合于我省的检测结核菌耐多药性的新方法。 相似文献
17.
氯硝柳胺悬浮剂的毒性评价 总被引:2,自引:2,他引:2
目的评价氯硝柳胺悬浮剂的毒性,为现场大规模应用灭螺提供依据。方法按照中华人民共和国国家标准GB 15670-1995《农药登记毒理学试验方法》和鱼类毒性试验方法进行。结果经口、经皮肤的LDso雌、雄性大鼠均>5 000 mg/kg,经呼吸道的LCso雌、雄性大鼠均>5 000mg/m3,该药经口、经皮肤、经呼吸道毒性均属微毒类药物;兔眼用药后,观察期内无不良反应,对眼无刺激性;皮肤用药后对皮肤无刺激性。与氯硝柳胺原药、氯硝柳胺乙醇胺盐原药和氯硝柳胺乙醇胺盐可湿性粉剂相比,氯硝柳胺悬浮剂对鱼急性毒性最低。结论氯硝柳胺悬浮剂属微毒类药物,对鱼的毒性低于其乙醇胺盐可湿性粉剂,适合于现场应用。 相似文献
18.
The aim of the study was to assess the quality of life (QOL) and the psychological status of parents of children with juvenile
chronic arthritis (JCA). The QOL, anxiety and depression of the parents of 28 children with JCA were evaluated and compared
to those of the parents of 28 healthy children. Mothers of JCA children and mothers of healthy children reported similar QOL.
The reported anxiety and depression levels were similar for mothers and fathers in both groups. The parents of children with
pauciarticular-type JCA reported lower QOL and higher levels of anxiety and depression than the parents of children with other
types, namely polyarticular and systemic JCA. These findings may be explained by the fact that the pauciarticular patients
had shorter disease duration and were less frequently seen in the outpatient clinic. The QOL of mothers of children with JCA
was found to be slightly impaired in the group of children with pauciarticular JCA. Future larger studies are needed to confirm
these results, as the number of subjects in the three groups was rather low.
Received: 26 September 2001 / Accepted: 8 February 2002 相似文献
19.
Marc B. Taub Thomas A. Peyser J. Erik Rosenquist 《Journal of diabetes science and technology》2007,1(5):685-694
Background
A 5-day in-patient study designed to assess the accuracy of the FreeStyle Navigator® Continuous Glucose Monitoring System revealed that the level of accuracy of the continuous sensor measurements was dependent on the rate of glucose change. When the absolute rate of change was less than 1 mg•dl−1•min−1 (75% of the time), the median absolute relative difference (ARD) was 8.5%, with 85% of all points falling within the A zone of the Clarke error grid. When the absolute rate of change was greater than 2 mg•dl−1•min−1 (8% of the time), the median ARD was 17.5%, with 59% of all points falling within the Clarke A zone.Method
Numerical simulations were performed to investigate effects of the rate of change of glucose on sensor measurement error. This approach enabled physiologically relevant distributions of glucose values to be reordered to explore the effect of different glucose rate-of-change distributions on apparent sensor accuracy.Results
The physiological lag between blood and interstitial fluid glucose levels is sufficient to account for the observed difference in sensor accuracy between periods of stable glucose and periods of rapidly changing glucose.Conclusions
The role of physiological lag on the apparent decrease in sensor accuracy at high glucose rates of change has implications for clinical study design, regulatory review of continuous glucose sensors, and development of performance standards for this new technology. This work demonstrates the difficulty in comparing accuracy measures between different clinical studies and highlights the need for studies to include both relevant glucose distributions and relevant glucose rate-of-change distributions. 相似文献20.
Toshihide Iijima M.D. 《Diseases of the colon and rectum》1988,31(1):46-49
Angiography using Prostaglandin El® was performed on 38 patients with carcinoma of the colon in order to diagnose the degree of serosal cancer invasion. The findings at angiography were classified into four groups:1) AG-S3, abnormal change (irregularity and/or encasement) up to marginal vessels; 2) AG-S2, abnormality up to vasa recta; 3) AG-S1, abnormality of penetrating branches of vasa recta within the wall of the colon; and 4) AG-S0, no distinct findings of abovementioned vessels. These angiographic findings were compared with both macroscopic and microscopic serosal cancer invasion. Angiographic diagnosis is in accord with the macroscopic findings in 84.2 percent of cases. Angiographic diagnosis is in accord with the microscopic findings in 32.4 percent of cases. Macroscopic findings confirm the angiographic diagnosis precisely but the conflict with microscopic findings should not be overlooked. This may be the result of inflammatory change, adhesion, and fibrosis around carcinoma of the colon. 相似文献